Light anti-thrombotic regimen for prevention of device thrombosis and/or thrombotic complications after interatrial shunts device-based closure
G Rigatelli, M Zuin, F Dell'Avvocata, L Roncon… - European Journal of …, 2020 - Elsevier
Aims The optimal antiplatelet therapy after atrial septal defect (ASD) or patent foramen ovale
device closure (PFO) remain to be established. We evaluated the safety and effectiveness of …
device closure (PFO) remain to be established. We evaluated the safety and effectiveness of …
Light anti-thrombotic regimen for prevention of device thrombosis and/or thrombotic complications after interatrial shunts device-based closure
G Rigatelli, M Zuin, F Dell'Avvocata, L Roncon… - European Journal of …, 2020 - ejinme.com
Aims The optimal antiplatelet therapy after atrial septal defect (ASD) or patent foramen ovale
device closure (PFO) remain to be established. We evaluated the safety and effectiveness of …
device closure (PFO) remain to be established. We evaluated the safety and effectiveness of …
[引用][C] Light anti-thrombotic regimen for prevention of device thrombosis and/or thrombotic complications after interatrial shunts device-based closure
G Rigatelli, M Zuin, F Dell'Avvocata, L Roncon… - European Journal of …, 2020 - cir.nii.ac.jp
Light anti-thrombotic regimen for prevention of device thrombosis and/or thrombotic
complications after interatrial shunts device-based closure | CiNii Research CiNii 国立情報学 …
complications after interatrial shunts device-based closure | CiNii Research CiNii 国立情報学 …
Light anti-thrombotic regimen for prevention of device thrombosis and/or thrombotic complications after interatrial shunts device-based closure.
G Rigatelli, M Zuin, F Dell'Avvocata… - European Journal of …, 2020 - europepmc.org
Aims The optimal antiplatelet therapy after atrial septal defect (ASD) or patent foramen ovale
device closure (PFO) remain to be established. We evaluated the safety and effectiveness of …
device closure (PFO) remain to be established. We evaluated the safety and effectiveness of …
Light anti-thrombotic regimen for prevention of device thrombosis and/or thrombotic complications after interatrial shunts device-based closure
G Rigatelli, M Zuin, F Dell'Avvocata… - … journal of internal …, 2020 - pubmed.ncbi.nlm.nih.gov
Aims The optimal antiplatelet therapy after atrial septal defect (ASD) or patent foramen ovale
device closure (PFO) remain to be established. We evaluated the safety and effectiveness of …
device closure (PFO) remain to be established. We evaluated the safety and effectiveness of …